Cantor Fitzgerald Maintains Overweight on Vanda Pharma, Raises Price Target to $13
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan maintains an Overweight rating on Vanda Pharmaceuticals (NASDAQ:VNDA) and raises the price target from $11 to $13.
August 01, 2024 | 4:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Charles Duncan maintains an Overweight rating on Vanda Pharmaceuticals and raises the price target from $11 to $13.
The raised price target and maintained Overweight rating from a reputable analyst at Cantor Fitzgerald is likely to positively impact VNDA's stock price in the short term as it signals confidence in the company's performance and potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100